GSK Winds Down German Flu Vaccine Plant, 650 Jobs Go

GSK is closing a vaccine manufacturing site in Germany and cutting about 650 jobs after a "rigorous review" of two sites, citing falling demand for egg-based flu vaccines, a company spokesperson told Endpoints News on Sept. 14, 2026.

GSK is shutting down a vaccine manufacturing site in Germany and cutting roughly 650 jobs, with the company pointing to falling demand for egg-based influenza vaccines as the reason. A GSK spokesperson confirmed the decision to Endpoints News, saying the closure followed a "rigorous review" of two sites.

The headline number — about 650 workers — makes this one of the larger single-site vaccine manufacturing retrenchments announced by a major European drugmaker in recent memory. But the more consequential detail is the stated cause. GSK is not blaming a pricing squeeze, a regulatory setback or a one-off contract loss. It is blaming the technology itself: eggs.

Why the egg-based platform is the problem

Egg-based flu vaccine manufacturing is roughly as old as industrial vaccinology. Candidate virus strains are injected into fertilised hen eggs, incubated, harvested, inactivated and purified. The method is cheap at scale and extraordinarily well understood by regulators, which is precisely why it survived so long. It is also slow, inflexible and physically enormous — a plant built for eggs is built for eggs, and converting one to cell-culture or recombinant production is closer to a rebuild than a retrofit.

That inflexibility is what turns soft demand into a closure rather than a slowdown. When volumes fall on a general-purpose fill-finish line, a manufacturer can reallocate capacity to another product. When volumes fall on a dedicated egg-based influenza line, the options narrow to running it below efficient scale or switching it off. GSK, on the evidence of this decision, chose the latter after reviewing the economics across two sites.

The demand backdrop has been moving against the platform for years. Newer influenza vaccines grown in mammalian cell culture or produced recombinantly avoid the egg-adaptation changes that can blunt how well a vaccine matches the circulating strain, and they decouple output from the supply of fertilised eggs. Buyers — national immunisation programmes, tender authorities, large pharmacy chains — have been shifting purchasing toward those newer formats and toward higher-dose and adjuvanted products aimed at older adults, where the pricing is better and the clinical case is stronger. Meanwhile, seasonal flu vaccination uptake in many wealthy countries has not recovered to the levels seen during the peak of pandemic-era public health messaging. Fewer doses sold, sold at lower prices, on the oldest platform in the portfolio, is a hard combination to defend to a capital allocation committee.

What it signals about GSK's manufacturing footprint

GSK's vaccines franchise has been rebuilt over the past several years around a smaller number of higher-value products — shingles, meningitis, respiratory protection for older adults — rather than around volume seasonal influenza. Seen against that strategy, a German egg-based flu plant is a legacy asset carrying legacy fixed costs, and the review of two sites suggests the company was explicitly comparing which footprint it wanted to keep.

The wind-down implies several things worth watching:

A one-time cost now, a lower cost base later. Site closures in Germany typically involve negotiated redundancy packages with works councils, which means the savings arrive with a lag behind the announcement.
Supply consolidation. Any residual egg-based flu output would need to be served from remaining sites or wound out of the portfolio entirely. Procurement bodies that still buy egg-based doses will want clarity on continuity of supply for coming seasons.
Pandemic preparedness questions. Egg-based capacity has long doubled as standby surge capacity for an influenza pandemic, often underpinned by government reservation contracts. Removing 650 workers' worth of capability from the European base invites scrutiny from health ministries about what replaces it.
A template for peers. GSK is not the only manufacturer sitting on ageing egg-based lines. A public closure by one of the largest players lowers the political cost of the next one.

How the shares traded on the day

The announcement landed on a soft session for equities broadly. As of the last trade at 16:35 GMT on Sept. 14, 2026, the S&P 500 tracker SPY was at $762.23, down 0.27% from the prior close of $764.29. The Nasdaq 100 proxy QQQ was at $710.40, off 0.63% against a previous close of $714.88, while the Dow 30 fund DIA was essentially flat at $525.74, down 0.01%.

GSK went the other way. The stock was quoted at 50.14 at the same timestamp, up 4.18% from a prior close of 48.13, and traded a day range of 49.61 to 50.30 — finishing the interval near the top of that band. In other words, the shares closed in on their intraday high while the two main U.S. equity benchmarks were lower.

In other words, the shares closed in on their intraday high while the two main U.

It would be a stretch to read a 4.18% move as a verdict on one factory. Restructuring news of this kind is rarely worth that much on its own, and nothing in the company's statement quantified the financial effect. What the move does confirm is that the market did not treat the closure as bad news — a cost-side decision on a declining product line is the kind of thing equity investors have generally rewarded in large-cap pharma, particularly when the capital freed up can be redirected toward higher-margin vaccines and specialty medicines.

The open questions

Three things remain unanswered from the company's confirmation. First, the timetable: "wind down" implies a phased exit rather than an immediate stop, and the pace will determine when the job losses actually bite and when the savings show up. Second, the fate of the second site in the review — the company said the closure followed a rigorous review of two sites, which raises the obvious question of what happens to the other one. Third, the financial framing: GSK has not put a charge, a savings figure or a segment impact on the record.

For the 650 employees, the German co-determination process means the terms of the exit will be negotiated rather than dictated, and the local labour market for skilled biologics manufacturing staff is a factor in how quickly people are reabsorbed. For the wider industry, the message is blunter. The egg has been the workhorse of influenza vaccination for generations. This is what its retirement looks like on a balance sheet.

Key facts

Jobs affected: About 650 workers at the German site
Stated reason: Declining demand for egg-based flu vaccines, following a "rigorous review" of two sites
GSK share price: 50.14, +4.18% (prev close 48.13), as of 16:35 GMT Sept. 14, 2026
Market backdrop: S&P 500 tracker SPY $762.23 (-0.27%); Nasdaq 100 proxy QQQ $710.40 (-0.63%)

Frequently asked questions

What exactly did GSK announce?

GSK confirmed it is winding down a vaccine manufacturing factory in Germany and laying off approximately 650 workers. A company spokesperson told Endpoints News that the decision followed a "rigorous review" of two sites and was driven by declining demand for egg-based influenza vaccines.

Why is demand for egg-based flu vaccines falling?

Egg-based production is the oldest influenza vaccine method, grown in fertilised hen eggs. Buyers have increasingly shifted toward cell-culture and recombinant vaccines, which avoid egg-adaptation strain mismatch and do not depend on egg supply, as well as toward higher-dose and adjuvanted products for older adults.

How did GSK shares react?

GSK was quoted at 50.14 as of the last trade at 16:35 GMT on Sept. 14, 2026, up 4.18% from a prior close of 48.13, with a day range of 49.61 to 50.30. That came on a session when the S&P 500 tracker was down 0.27% and the Nasdaq 100 proxy down 0.63%.

Has GSK said what the closure will cost or save?

No. The company confirmed the closure and the approximate number of jobs affected but did not disclose a restructuring charge, an expected annual saving, or an impact on vaccine segment revenue. German site closures typically involve negotiated redundancy terms, so savings usually lag the announcement.

Why can't the plant just switch to making other vaccines?

Egg-based influenza facilities are purpose-built around incubating and harvesting fertilised eggs. Converting one to cell-culture or recombinant manufacturing is closer to a rebuild than a retrofit, which is why weak volumes on a dedicated egg line tend to end in closure rather than product reallocation.

Does this affect pandemic flu preparedness?

It raises the question. Egg-based capacity has historically doubled as standby surge capacity for an influenza pandemic, often backed by government reservation contracts. Removing a site of this size from the European manufacturing base is likely to draw questions from health authorities about what replaces that capability.

Sources

GSK to wind down German vaccine factory due to lack of demand — Endpoints News

Photo: EqualStock IN · Pexels Licence — source